Mavacamten is a cardiac myosin inhibitor approved for the treatment of obstructive hypertrophic cardiomyopathy. This page provides a comparison of Mavacamten with Aficamten (Myqorzo).
Mavacamten Alternatives: How It Compares to Other Cardiac Myosin Inhibitors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/4 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
Mavacamten, approved in 2022, precedes Myqorzo (Aficamten), which received approval in 2025. Meanwhile, HRS-1893 is still in Phase 3, trailing these approved therapies by approximately 1-2 years.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Mavacamten (Camzyos) | Cardiac myosin inhibitor | Obstructive hypertrophic cardiomyopathy | 2.5 mg to 15 mg orally once daily | 2022 | Composite functional response (pVO2 and NYHA class improvement): 37% @ 30 weeks | $90k |
| Aficamten (Myqorzo) | Cardiac myosin inhibitor | symptomatic obstructive hypertrophic cardiomyopathy | Oral, once daily | 2025 | change in peak oxygen uptake (pVO2): 1.8mL/kg/min @ 24 weeks | $108k |
| Aficamten (Myqorzo) | Cardiac myosin inhibitor | Symptomatic obstructive hypertrophic cardiomyopathy | 5 mg to 20 mg orally once daily | 2025 | Placebo-adjusted change in peak oxygen uptake (pVO2): 1.74mL/kg/min @ 24 weeks | — |
| HRS-1893 | Cardiac myosin inhibitor | — | 40 mg or 60 mg twice daily | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Change in pVO2; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for hypertrophic cardiomyopathy specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Mavacamten vs Aficamten (Myqorzo)
No head-to-head Phase-3 trial directly compares Mavacamten with Aficamten.
In separate pivotal trials, Mavacamten reported 37% Composite functional response (pVO2 and NYHA class improvement) at 30 weeks (NCT03470545) versus 1.8mL/kg/min change in peak oxygen uptake (pVO2) at 24 weeks for Aficamten (NCT05186818).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Mavacamten vs Aficamten (Myqorzo)
No head-to-head Phase-3 trial directly compares Mavacamten with Aficamten.
In separate pivotal trials, Mavacamten reported 37% Composite functional response (pVO2 and NYHA class improvement) at 30 weeks (NCT03470545) versus 1.74mL/kg/min Placebo-adjusted change in peak oxygen uptake (pVO2) at 24 weeks for Aficamten (NCT05186818).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Several investigational IL-17 related drugs are in active clinical development. Among these is HRS-1893, an IL-17 inhibitor from Shandong Suncadia Medicine Co., Ltd., currently undergoing a lead Phase 3 trial identified as NCT07021976. This drug represents a different therapeutic approach compared to cardiac myosin inhibitors like Mavacamten, specifically targeting the IL-17 pathway.
Choosing between Mavacamten and its alternatives
When choosing between cardiac myosin inhibitors, clinicians consider a range of factors including established clinical experience, efficacy, and dosing convenience. Mavacamten, as an available option, may be preferred by some prescribers due to its longer track record in clinical practice and a well-understood safety profile. In contrast, Aficamten (Myqorzo) offers an oral, once-daily regimen with a flexible dosing range of 5 mg to 20 mg. Clinical studies have shown Aficamten to achieve a change in peak oxygen uptake (pVO2) of 1.8 mL/kg/min at 24 weeks, with a placebo-adjusted change of 1.74 mL/kg/min over the same period.
Conversely, an alternative cardiac myosin inhibitor like Aficamten might be chosen based on its specific clinical profile, such as the observed change in pVO2 of 1.74 mL/kg/min. Other considerations, including potential differences in safety profiles, dosing flexibility, or cost-effectiveness, could also guide selection. For instance, a newer agent might be preferred if it offers a distinct adverse event profile or a more convenient dosing schedule for specific patient needs.
This information is for educational purposes only and does not constitute medical advice. Clinical decisions regarding patient care should always be made by a qualified prescriber.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
mavacamtenmavacamten alternativesalternativescomparisonhypertrophic cardiomyopathymavacamten-cardiac-myosin-inhibitor-hcmmavacamten vs aficamtenmavacamten vs hrs-1893mavacamten vs aficamten